Spark Therapeutics, Pfizer Present Updated Data From Ongoing SPK-9001 Trial

Spark Therapeutics (ONCE) and Pfizer Inc. (PFE) announced updated results of the first cohort from the ongoing Phase 1/2 clinical trial of SPK-9001, the lead investigational candidate in the companies' SPK-FIX program, in development for the treatment of hemophilia B as a potential one-time therapy.

from RTT - Biotech http://ift.tt/2a8Cey3
via IFTTT